Nes-Ziona, Israel, May  15, 2026  (GLOBE NEWSWIRE) --  Enlivex Ltd. (NASDAQ:ENLV, &#34;Enlivex&#34; or the &#34;Company&#34;)), a quality longevity company powered by a prediction markets treasury, today announced that it has received a

ENLV

Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification

Enlivex Faces Nasdaq Compliance Challenge for Share Price

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Nes-Ziona, Israel, May  15, 2026  (GLOBE NEWSWIRE) --  Enlivex Ltd. (NASDAQ:ENLV, &amp;#34;Enlivex&amp;#34; or the &amp;#34;Company&amp;#34;)), a quality longevity company powered by a prediction markets treasury, today announced that it has received a</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Enlivex Ltd. has received a notice from Nasdaq regarding non-compliance with bid price requirements. The company has until November 9, 2026, to meet the $1.00 minimum bid, which could affect its future trading status significantly.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Enlivex receives Nasdaq notice for low bid price compliance.</li><li>Company has until November 9, 2026, to regain compliance.</li><li>A second 180-day extension may be possible if needed.</li><li>Failure to comply could lead to delisting and market implications.</li><li>Current operations and listing status remain unaffected by notice.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>NASDAQ (NDAQ)</strong>: Monitors compliance standards affecting ENLV&#039;s listing.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; due to the compliance challenge with Nasdaq, impacting investor sentiment and share stability.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>If ENLV shares remain below $1.00, delisting risk will increase.</li><li>Possible reverse stock split may be considered to boost share price.</li><li>Market reaction could accelerate if compliance is not demonstrated soon.</li><li>Investors may need to reassess holdings in ENLV leading up to compliance deadlines.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Enlivex received Nasdaq notice on May 15, 2026.</li><li>Deadline for compliance is November 9, 2026.</li><li>Share must close above $1.00 for at least 10 days.</li><li>Enlivex may qualify for a second 180-day extension.</li><li>A reverse stock split could be a potential strategy.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider potential volatility in ENLV as compliance deadlines approach.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>Nes-Ziona, Israel, May  15, 2026  (GLOBE NEWSWIRE) --  Enlivex Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ENLV">ENLV</a>, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today announced that it has received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), stating that the  closing bid price of the Company's ordinary shares during the 30 consecutive business days prior to the date of the Notice did not meet the $1.00 minimum bid price requirement in accordance with Nasdaq Listing Rule 5550(a)(2).</p>  <p>Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until November 9, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the ordinary shares must be at least $1.00 for a minimum of 10 consecutive business days (with such compliance period extendable at the discretion of Nasdaq) prior to November 9, 2026. Nasdaq would then provide a written confirmation of compliance, and the matter will be closed.</p>  <p>If the Company is unable to regain compliance by November 9, 2026, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the minimum bid price requirement. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary, and it must otherwise appear to Nasdaq that the Company is capable of curing the deficiency. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180 calendar day period, then Nasdaq will notify the Company that its ordinary shares are subject to delisting, at which time the Company would have an opportunity to appeal the delisting determination to a Hearings Panel.</p>  <p>The Company will monitor the closing bid price of its ordinary shares.  Receipt of the Notice has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, nor does receipt of the Notice have any effect on the Company's business operations.</p>  <p><b>About Enlivex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ENLV">ENLV</a>)</b></p>  <p>Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra&#x2122;, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis.</p>  <p>In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN token, which is the token of the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.</p>  <p><b>Forward-Looking Statements</b></p>  <p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA&#x2122; programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.</p>  <p><b>ENLIVEX CONTACT</b></p>  <p>Shachar Shlosberger, CFO<br></br>Enlivex Ltd.<br></br><a href="https://www.globenewswire.com/Tracker?data=qKNivNswJFvPjUICabq4BdNbfQpfO3Wljo008GOt2QkGZ18Teu_QjYWOiXTB09T9zs6mdwU5VFjZaVo99wR2NIXsH9e6-uZoUkBV4kV2tmg=" rel="nofollow" target="_blank">shachar@enlivex.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMTQyNCM3NjA2MzQ4IzUwMDA2NTE3NA=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NTc0YmM5NDMtN2I1Yi00MWE0LTljM2QtYjc1OWYyNTEwYjIwLTUwMDA2NTE3NC0yMDI2LTA1LTE1LWVu/tiny/Enlivex-Ltd-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/27d4e006-8709-4fd1-8341-5b58381487d4"><img src="https://ml.globenewswire.com/media/27d4e006-8709-4fd1-8341-5b58381487d4/small/picture1-jpg.jpg" border="0" width="150" height="37" alt="Primary Logo"></img></a></p>

Enlivex Ltd. has received a notice from Nasdaq regarding non-compliance with bid price requirements. The company has until November 9, 2026, to meet the $1.00 minimum bid, which could affect its future trading status significantly.

Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News